The medicines development process' ultimate goal is an approval for marketing the new medicinal product – a Marketing Authorisation. This should be an integral part of all steps throughout...
Epidemiology is the underlying and basic science of public health. It could be defined as any research of health events in populations, including: how many are affected by such...
Diagnosed with MS and then …. When I got my diagnosis in 2005, I didn’t know a lot about multiple sclerosis. I was absolutely uninformed. Why should we think...
Discover why patients’ voices matter by following David, Dimitrios, and Jan and how they have a voice in medicines R&D. How can EUPATI play a role to help patient...
Guidance for Reporting and Dissemination of Patient Engagement Activities Background/Rationale for the document The complete and reliable reporting and dissemination of all patient engagement (PE) activities is essential...
”Enhance your reading experience by turning on the subtitles of the accompanying video.” Transcript [What training does a patient need in order to participate in a HTA process?] Jan...
Note: This webinar took place on 5 July 2017. You can find a video recording and the presentations used during the webinar below. Webinar introduction A very important result from the...
During clinical development the manufacturing and distribution facilities available may not be suitable for a trial medicine (investigational medicinal product (IMP)), however, IMPs must be manufactured, stored and distributed...